NCT05119335 2025-11-12
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
Phase 1/2 Terminated
NiKang Therapeutics, Inc.
University Hospital of North Norway
Maastricht Radiation Oncology
Threshold Pharmaceuticals
Threshold Pharmaceuticals
Siemens Molecular Imaging